Almirall to grow dermatology portfolio with acquisition of Poli Group

30 November 2015

In another acquisition move, Spain’s largest pharma company Almirall (ALM: MC) has signed an agreement to acquire 100% of the share capital of the Switzerland-headquartered Poli Group Holdings.

The holding company comprises three operating companies (Taurus Pharma GmbH, Polichem SA and Polichem Srl), and the transactions has an enterprise valuefor 365 million euros ($386.3 million). Almirall may pay additional 35 million euros in earn-outs once certain development milestones in the Poli Group are met.

With this strategic transaction, Almirall continues to execute on the plan to become a top global Dermatology player announced last year after the transfer agreement with AstraZeneca (LSE: AZN), which transferred rights to its proprietary respiratory franchise, including Eklira to AstraZeneca last year for around $875 million of initial consideration (The Pharma Letter November 3, 2014).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK